科伦药业：子公司产品芦康沙妥珠单抗(sac-TMT)获批第三项适应症

Core Viewpoint - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate, sac-TMT (also known as SKB264/MK-2870), for a third indication in treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1] Group 1 - Kelong Pharmaceutical's subsidiary, Sichuan Kelong Botai, has developed an ADC targeting TROP2 [1] - The newly approved indication is specifically for EGFR gene mutation-positive NSCLC patients [1] - This approval marks the third indication for sac-TMT, enhancing its therapeutic applications [1]